Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$157.96 USD
+1.05 (0.67%)
Updated Jun 27, 2024 04:00 PM ET
After-Market: $158.18 +0.22 (0.14%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 421 - 440 ( 663 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Briefing Documents Show up Early, More Negative Than We Expected; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan. 11th
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
On the January DMD Docket - A Drisa Decision and Eteplirsen Panel
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 21st
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Transferring Covaerage
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q15 in Line and All Systems Go; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 2This report contains brief updates on the following: DYAX, ANAC, IRWD, ECYT, FATE, XNCR, RGLS, MGNX, FCSC, SNSS, INFI, MDVN, RPTP, SRPT, XOMA, AGTC, EPZM, BLUE, PTCT, CATB, EPRS, ABUS, ICPT. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals: Potential Ripple Effect of Drisapersen''s Advisory Panel
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Advisory Committee Meeting Set for January 22nd, 2016
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D